{"count": 151, "results": [{"_id": "35270043", "pmid": 35270043, "pmcid": "PMC8910924", "title": "Targeting Myotonic Dystrophy Type 1 with Metformin", "journal": "Int J Mol Sci", "authors": ["García-Puga M", "Saenz-Antoñanzas A", "Matheu A", "López de Munain A"], "date": "2022-03-07T00:00:00Z", "doi": "10.3390/ijms23052901", "meta_date_publication": "2022 Mar 7", "meta_volume": "23", "meta_issue": "5", "meta_pages": "", "score": 50291.31, "text_hl": "Targeting @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@Myotonic Dystrophy Type 1@@@ with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@", "citations": {"NLM": "García-Puga M, Saenz-Antoñanzas A, Matheu A, López de Munain A. Targeting Myotonic Dystrophy Type 1 with Metformin Int J Mol Sci. 2022 Mar 7;23(5):. PMID: 35270043", "BibTeX": "@article{35270043, title={Targeting Myotonic Dystrophy Type 1 with Metformin}, author={García-Puga M and Saenz-Antoñanzas A and Matheu A and López de Munain A}, journal={Int J Mol Sci}, volume={23}, number={5}}"}}, {"_id": "33798646", "pmid": 33798646, "pmcid": "PMC8372527", "title": "Myotonic dystrophy type 1 drug development: A pipeline toward the market", "journal": "Drug Discov Today", "authors": ["Pascual-Gilabert M", "López-Castel A", "Artero R"], "date": "2021-07-01T00:00:00Z", "doi": "10.1016/j.drudis.2021.03.024", "meta_date_publication": "2021 Jul", "meta_volume": "26", "meta_issue": "7", "meta_pages": "1765-1772", "score": 50267.137, "text_hl": "Of these, repurposing of @CHEMICAL_tideglusib @CHEMICAL_MESH:C520571 @@@tideglusib@@@, @CHEMICAL_Mexiletine @CHEMICAL_MESH:D008801 @@@mexiletine@@@, or @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ appear to be therapies with the most potential to receive marketing authorization for @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM1@@@.", "citations": {"NLM": "Pascual-Gilabert M, López-Castel A, Artero R. Myotonic dystrophy type 1 drug development: A pipeline toward the market Drug Discov Today. 2021 Jul;26(7):1765-1772. PMID: 33798646", "BibTeX": "@article{33798646, title={Myotonic dystrophy type 1 drug development: A pipeline toward the market}, author={Pascual-Gilabert M and López-Castel A and Artero R}, journal={Drug Discov Today}, volume={26}, number={7}, pages={1765-1772}}"}}, {"_id": "32310829", "pmid": 32310829, "pmcid": "PMC7185118", "title": "Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin", "journal": "Aging (Albany NY)", "authors": ["García-Puga M", "Saenz-Antoñanzas A", "Fernández-Torrón R", "Munain AL", "Matheu A"], "date": "2020-04-08T00:00:00Z", "doi": "10.18632/aging.103022", "meta_date_publication": "2020 Apr 8", "meta_volume": "12", "meta_issue": "7", "meta_pages": "6260-6275", "score": 50263.742, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ restores additional @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM1@@@-associated phenotypes", "citations": {"NLM": "García-Puga M, Saenz-Antoñanzas A, Fernández-Torrón R, Munain AL, Matheu A. Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin Aging (Albany NY). 2020 Apr 8;12(7):6260-6275. PMID: 32310829", "BibTeX": "@article{32310829, title={Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin}, author={García-Puga M and Saenz-Antoñanzas A and Fernández-Torrón R and Munain AL and Matheu A}, journal={Aging (Albany NY)}, volume={12}, number={7}, pages={6260-6275}}"}}, {"_id": "33990102", "pmid": 33990102, "title": "New developments in myotonic dystrophies from a multisystemic perspective.", "journal": "Curr Opin Neurol", "authors": ["Montagnese F", "Schoser B"], "date": "2021-10-01T00:00:00Z", "doi": "10.1097/WCO.0000000000000964", "meta_date_publication": "2021 Oct 1", "meta_volume": "34", "meta_issue": "5", "meta_pages": "738-747", "score": 50263.68, "text_hl": "The alteration of @GENE_INS @GENE_3630 @@@insulin@@@ signaling pathways, involved in @DISEASE_Gastrointestinal_Diseases @DISEASE_MESH:D005767 @@@gastrointestinal manifestations@@@, @DISEASE_Carcinogenesis @DISEASE_MESH:D063646 @@@carcinogenesis@@@, muscle function, cognitive and endocrinological aspects, gain further relevance in the light of recent evidence of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ efficacy in @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM1@@@. ", "citations": {"NLM": "Montagnese F, Schoser B. New developments in myotonic dystrophies from a multisystemic perspective. Curr Opin Neurol. 2021 Oct 1;34(5):738-747. PMID: 33990102", "BibTeX": "@article{33990102, title={New developments in myotonic dystrophies from a multisystemic perspective.}, author={Montagnese F and Schoser B}, journal={Curr Opin Neurol}, volume={34}, number={5}, pages={738-747}}"}}, {"_id": "37975061", "pmid": 37975061, "pmcid": "PMC10653203", "title": "High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice", "journal": "J Pharm Pharmacol Res", "authors": ["Alvidrez RIM", "Annarapu GK", "Srinivasan AJ", "Liu Z", "Yazdani HO", "Nolfi-Donegan D", "Simmons RL", "Shiva S", "Neal MD"], "date": "2023-01-01T00:00:00Z", "meta_date_publication": "2023", "meta_volume": "7", "meta_issue": "4", "meta_pages": "192-202", "score": 50263.42, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is the most prescribed medication in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes Mellitus@@@(@<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM@@@). ", "citations": {"NLM": "Alvidrez RIM, Annarapu GK, Srinivasan AJ, Liu Z, Yazdani HO, Nolfi-Donegan D, Simmons RL, Shiva S, Neal MD. High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice J Pharm Pharmacol Res. 2023;7(4):192-202. PMID: 37975061", "BibTeX": "@article{37975061, title={High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice}, author={Alvidrez RIM and Annarapu GK and Srinivasan AJ and Liu Z and Yazdani HO and Nolfi-Donegan D and Simmons RL and Shiva S and Neal MD}, journal={J Pharm Pharmacol Res}, volume={7}, number={4}, pages={192-202}}"}}, {"_id": "39888448", "pmid": 39888448, "title": "Sarcopenia in independent oldest-old individuals treated for diabetes, with or without metformin: a case-control study.", "journal": "Acta Diabetol", "authors": ["Aguiar MB", "Kim S", "Bortoluzzo AB", "Di Tommaso AB", "Cendoroglo MS", "Colleoni GWB"], "date": "2025-01-31T00:00:00Z", "doi": "10.1007/s00592-025-02448-9", "meta_date_publication": "2025 Jan 31", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50262.773, "text_hl": "RESULTS: The prevalence of @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM@@@ was 24.7%, of which 56.25% used @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MTF@@@. ", "citations": {"NLM": "Aguiar MB, Kim S, Bortoluzzo AB, Di Tommaso AB, Cendoroglo MS, Colleoni GWB. Sarcopenia in independent oldest-old individuals treated for diabetes, with or without metformin: a case-control study. Acta Diabetol. 2025 Jan 31;():. PMID: 39888448", "BibTeX": "@article{39888448, title={Sarcopenia in independent oldest-old individuals treated for diabetes, with or without metformin: a case-control study.}, author={Aguiar MB and Kim S and Bortoluzzo AB and Di Tommaso AB and Cendoroglo MS and Colleoni GWB}, journal={Acta Diabetol}}"}}, {"_id": "34083618", "pmid": 34083618, "pmcid": "PMC8175603", "title": "Low metformin dose and its therapeutic serum concentration in prediabetes", "journal": "Sci Rep", "authors": ["Sutkowska E", "Fortuna P", "Wisniewski J", "Sutkowska K", "Hodurek P", "Gamian A", "Kaluza B"], "date": "2021-06-03T00:00:00Z", "doi": "10.1038/s41598-021-91174-7", "meta_date_publication": "2021 Jun 3", "meta_volume": "11", "meta_issue": "1", "meta_pages": "11684", "score": 50262.703, "text_hl": "Twenty @SPECIES_9606 @@@patients@@@ with new-diagnosed pre-@<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM@@@ were treated with a 1500 mg/day regimen of the @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for 15 weeks. ", "citations": {"NLM": "Sutkowska E, Fortuna P, Wisniewski J, Sutkowska K, Hodurek P, Gamian A, Kaluza B. Low metformin dose and its therapeutic serum concentration in prediabetes Sci Rep. 2021 Jun 3;11(1):11684. PMID: 34083618", "BibTeX": "@article{34083618, title={Low metformin dose and its therapeutic serum concentration in prediabetes}, author={Sutkowska E and Fortuna P and Wisniewski J and Sutkowska K and Hodurek P and Gamian A and Kaluza B}, journal={Sci Rep}, volume={11}, number={1}, pages={11684}}"}}, {"_id": "37503167", "pmid": 37503167, "pmcid": "PMC10371086", "title": "High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice", "journal": "Res Sq", "authors": ["Alvidrez RIM", "Annarapu GK", "Sriniv AJ", "Liu Z", "Yazdani HO", "Simmons RL", "Shiva S", "Neal MD", "Nolfi-Donegan D"], "date": "2023-07-11T00:00:00Z", "doi": "10.21203/rs.3.rs-3143156/v1", "meta_date_publication": "2023 Jul 11", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50261.973, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is the most prescribed medication in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes Mellitus@@@(@<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM@@@). ", "citations": {"NLM": "Alvidrez RIM, Annarapu GK, Sriniv AJ, Liu Z, Yazdani HO, Simmons RL, Shiva S, Neal MD, Nolfi-Donegan D. High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice Res Sq. 2023 Jul 11;():. PMID: 37503167", "BibTeX": "@article{37503167, title={High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice}, author={Alvidrez RIM and Annarapu GK and Sriniv AJ and Liu Z and Yazdani HO and Simmons RL and Shiva S and Neal MD and Nolfi-Donegan D}, journal={Res Sq}}"}}, {"_id": "38089917", "pmid": 38089917, "pmcid": "PMC10711185", "title": "Metformin: A potential adjunct for treatment of systemic mastocytosis", "journal": "J Allergy Clin Immunol Glob", "authors": ["Butterfield JH", "Bartemes K"], "date": "2023-11-07T00:00:00Z", "doi": "10.1016/j.jacig.2023.100186", "meta_date_publication": "2024 Feb", "meta_volume": "3", "meta_issue": "1", "meta_pages": "100186", "score": 50261.926, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ remains an inexpensive and widely used treatment for @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM2@@@, and studies have shown that there is a reduced risk of @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM2@@@ treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Butterfield JH, Bartemes K. Metformin: A potential adjunct for treatment of systemic mastocytosis J Allergy Clin Immunol Glob. 2024 Feb;3(1):100186. PMID: 38089917", "BibTeX": "@article{38089917, title={Metformin: A potential adjunct for treatment of systemic mastocytosis}, author={Butterfield JH and Bartemes K}, journal={J Allergy Clin Immunol Glob}, volume={3}, number={1}, pages={100186}}"}}, {"_id": "37009001", "pmid": 37009001, "pmcid": "PMC10008389", "title": "Comparison of the anti-diabetic and nephroprotective activities of vitamin E, metformin, and Nigella sativa oil on kidney in experimental diabetic rats", "journal": "Iran J Basic Med Sci", "authors": ["Ayaz H", "Kaya S", "Seker U", "Nergiz Y"], "date": "2023-04-01T00:00:00Z", "doi": "10.22038/IJBMS.2023.68051.14876", "meta_date_publication": "2023 Apr", "meta_volume": "26", "meta_issue": "4", "meta_pages": "395-399", "score": 50260.684, "text_hl": " Thirty male Wistar Albino @SPECIES_10116 @@@rats@@@ were randomly divided into control, experimental @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ (@<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM@@@), @CHEMICAL_Vitamin_E @CHEMICAL_MESH:D014810 @@@vitamin E@@@ + @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ + @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM@@@, and N. sativa + @<m>DISEASE_Myotonic_Dystrophy</m> @DISEASE_MESH:D009223 @@@DM@@@. ", "citations": {"NLM": "Ayaz H, Kaya S, Seker U, Nergiz Y. Comparison of the anti-diabetic and nephroprotective activities of vitamin E, metformin, and Nigella sativa oil on kidney in experimental diabetic rats Iran J Basic Med Sci. 2023 Apr;26(4):395-399. PMID: 37009001", "BibTeX": "@article{37009001, title={Comparison of the anti-diabetic and nephroprotective activities of vitamin E, metformin, and Nigella sativa oil on kidney in experimental diabetic rats}, author={Ayaz H and Kaya S and Seker U and Nergiz Y}, journal={Iran J Basic Med Sci}, volume={26}, number={4}, pages={395-399}}"}}]}